Impaired fast-spiking, suppressed cortical inhibition, and increased susceptibility to seizures in mice lacking Kv3.2 K+ channel proteins.
Voltage-gated K(+) channels of the Kv3 subfamily have unusual electrophysiological properties, including activation at very depolarized voltages (positive to -10 mV) and very fast deactivation rates, suggesting special roles in neuronal excitability. In the brain, Kv3 channels are prominently expressed in select neuronal populations, which include fast-spiking (FS) GABAergic interneurons of the neocortex, hippocampus, and caudate, as well as other high-frequency firing neurons. Although evidence points to a key role in high-frequency firing, a definitive understanding of the function of these channels has been hampered by a lack of selective pharmacological tools. We therefore generated mouse lines in which one of the Kv3 genes, Kv3.2, was disrupted by gene-targeting methods. Whole-cell electrophysiological recording showed that the ability to fire spikes at high frequencies was impaired in immunocytochemically identified FS interneurons of deep cortical layers (5-6) in which Kv3.2 proteins are normally prominent. No such impairment was found for FS neurons of superficial layers (2-4) in which Kv3.2 proteins are normally only weakly expressed. These data directly support the hypothesis that Kv3 channels are necessary for high-frequency firing. Moreover, we found that Kv3.2 -/- mice showed specific alterations in their cortical EEG patterns and an increased susceptibility to epileptic seizures consistent with an impairment of cortical inhibitory mechanisms. This implies that, rather than producing hyperexcitability of the inhibitory interneurons, Kv3.2 channel elimination suppresses their activity. These data suggest that normal cortical operations depend on the ability of inhibitory interneurons to generate high-frequency firing.
Lau
D
D
Departments of Physiology and Neuroscience, and Biochemistry, New York University School of Medicine, New York, New York 10016, USA.
Vega-Saenz de Miera
E C
EC
Contreras
D
D
Ozaita
A
A
Harvey
M
M
Chow
A
A
Noebels
J L
JL
Paylor
R
R
Morgan
J I
JI
Leonard
C S
CS
Rudy
B
B
D000200:Action Potentials / Q000235:genetics; D000818:Animals; D001522:Behavior, Animal; D002540:Cerebral Cortex / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology*; D003001:Cloning, Molecular; D004569:Electroencephalography; D005260:Female; D018390:Gene Targeting; D020022:Genetic Predisposition to Disease; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009433:Neural Inhibition / Q000187:drug effects / Q000235:genetics; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009479:Neuropeptides / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010641:Phenotype; D015221:Potassium Channels / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D024642:Potassium Channels, Voltage-Gated; D012640:Seizures / Q000235:genetics / Q000503:physiopathology*; D051670:Shaw Potassium Channels; D013234:Stem Cells; D019789:Tetraethylammonium / Q000494:pharmacology
D009479:Neuropeptides; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D051670:Shaw Potassium Channels; D019789:Tetraethylammonium